Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer
NCT ID: NCT02324114
Last Updated: 2014-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1100 participants
INTERVENTIONAL
2012-09-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rectal cancer
Detect plasma Hsp90α concentration of patients,
Hsp90
Detect plasma Hsp90α concentration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hsp90
Detect plasma Hsp90α concentration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Protgen Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinming Yu, MD
Role: PRINCIPAL_INVESTIGATOR
Shandong province cancer hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shandong province cancer hospital
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Xianrang Song, MD
Role: CONTACT
Phone: 0531
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lisheng Liu, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
hsp90a2011-03
Identifier Type: -
Identifier Source: org_study_id